13F Holdings
中文EN

ERAS Erasca, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—

Leverage & solvency

Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$92.85M$115.36M$103.82M$112.46M$73.92M
SG&A expense$38.55M$41.73M$37.70M$32.99M$22.62M
Operating income-$140.91M-$179.59M-$141.53M-$247.45M-$124.88M
Pretax income-$124.55M-$161.65M———
Income tax$0$0———
Net income-$124.55M-$161.65M-$125.04M-$242.81M-$122.76M
EBITDA-$137.80M-$175.78M-$137.79M-$244.81M-$124.05M
EPS (basic)-0.44-0.69-0.83-1.99-1.85
EPS (diluted)-0.44-0.69-0.83-1.99-1.85
Dividends declared per share0.000.000.000.00—
Weighted avg. shares (diluted)283.53M233.82M150.18M122.02M66.29M
Balance sheet
Cash & equivalents$73.81M$67.74M$93.08M$284.22M$360.49M
Short-term investments$202.27M$230.57M$219.28M$151.40M$53.99M
Current assets$286.24M$308.79M$320.68M$444.50M$420.02M
PP&E, net$13.30M$16.32M$22.33M$24.82M$15.95M
Total assets$396.15M$502.53M$395.30M$514.91M$501.42M
Current liabilities$28.51M$31.39M$26.16M$48.69M$26.22M
Total liabilities$70.98M$79.03M$78.61M$103.06M$44.89M
Shareholders' equity$325.17M$423.50M$316.69M$411.85M$456.53M
Shares outstanding284.16M283.22M151.09M149.33M119.10M
Cash flow statement
Operating cash flow-$95.45M-$109.42M-$101.22M-$103.26M-$79.60M
Capital expenditure$128,000$60,000$1.77M$14.55M$11.21M
Free cash flow-$95.58M-$109.48M-$102.99M-$117.81M-$90.81M
Investing cash flow$100.42M-$156.62M-$91.22M-$71.08M-$64.59M
Financing cash flow$1.10M$240.70M$1.29M$98.08M$439.40M
Depreciation & amortization$3.11M$3.81M$3.73M$2.64M$829,000
Stock-based compensation$24.90M$26.97M$26.23M$20.11M$8.33M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.